Polyneuropathy Clinical Trial
Official title:
Neuromuscular Electrical Stimulation in the Critically Ill
Verified date | May 2018 |
Source | Brugmann University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Neuromuscular stimulation (NMES) has been used for several years in the rehabilitation of
COPD (chronic obstructive pulmonary disease) patients (among others) to improve their
resistance to efforts in everyday life. In patients in intensive care, it seems to improve
strength, reduce the loss of muscle mass, prevent the development of CIP / CIM (Critical
illness polyneuropathy / critical illness myopathy) and perhaps even reduce ventilation days,
with expected effects on the duration of hospitalization and the long-term functional
outcome. Although its use could sometimes be limited by the development of peripheral edema
and use of vasoconstrictors, the main advantage of this technique is the possibility of being
used very early, even in patients that require deep sedation . This is extremely important
given that the muscular atrophy process already starts 18h after the onset of invasive
ventilation and as signs of impaired nerve transmission are developed in one third of
patients at risk within 72 hours.
The purpose of the study is to assess the effects, in the short and medium term, of early
neuromuscular stimulation in patients who are at higher risk of developing a critical illness
polyneuropathy (CIP) / critical illness myopathy (CIM) spectrum disease.
This is a randomized controlled single-blind study comparing a group of patients submitted to
NMES early (up to 5 days after admission) versus a control group unstimulated.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | May 30, 2018 |
Est. primary completion date | May 30, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Admission in the ICU of the Brugmann Hospital (Unit 1020) with an intended ICU stay superior to 3 days - Aged over 18 years - Respiratory assistance needed (invasive and non-invasive ventilation, CPAP or Optiflow and PaO2(arterial oxygen pressure)/FiO2(fraction of inhaled oxygen)<200mmHg) - SAPSII (Simplified Acute Physiology Score) between entre 35 et 70. Exclusion Criteria: Definitive exclusion criteria: - patients bearing a pacemaker or an AICD (automatic implantable cardioverter/defibrillator ) - BMI superior to 35 - serious neuromuscular pathologies or alterations in the inferior members that make both tights stimulation impossible - pregnant women - patients admitted from Friday evening to Sunday morning Temporary exclusion criteria: - Hemodynamic instability (even with filling up and amines: noradrenaline > 0.5y/kg/min and/or dobutamine >5y/kg/min and/or adrenaline ivc) - Extreme severity with suspicion of death within the first 24 h - PIC > 20 cmH2O - Severe agitation (RASS > +1) - Curare utilisation within the last 24h |
Country | Name | City | State |
---|---|---|---|
Belgium | CHU Brugmann | Brussels |
Lead Sponsor | Collaborator |
---|---|
Brugmann University Hospital |
Belgium,
Batt J, dos Santos CC, Cameron JI, Herridge MS. Intensive care unit-acquired weakness: clinical phenotypes and molecular mechanisms. Am J Respir Crit Care Med. 2013 Feb 1;187(3):238-46. doi: 10.1164/rccm.201205-0954SO. Epub 2012 Nov 29. Review. — View Citation
Burke D, Gorman E, Stokes D, Lennon O. An evaluation of neuromuscular electrical stimulation in critical care using the ICF framework: a systematic review and meta-analysis. Clin Respir J. 2016 Jul;10(4):407-20. doi: 10.1111/crj.12234. Epub 2014 Nov 26. Review. — View Citation
Dal-Pizzol F, Ritter C. Functional disability 5 years after ARDS. N Engl J Med. 2011 Jul 21;365(3):274-5; author reply 275-6. doi: 10.1056/NEJMc1105509. — View Citation
Denehy L, de Morton NA, Skinner EH, Edbrooke L, Haines K, Warrillow S, Berney S. A physical function test for use in the intensive care unit: validity, responsiveness, and predictive utility of the physical function ICU test (scored). Phys Ther. 2013 Dec;93(12):1636-45. doi: 10.2522/ptj.20120310. Epub 2013 Jul 25. — View Citation
Dirks ML, Wall BT, Snijders T, Ottenbros CL, Verdijk LB, van Loon LJ. Neuromuscular electrical stimulation prevents muscle disuse atrophy during leg immobilization in humans. Acta Physiol (Oxf). 2014 Mar;210(3):628-41. doi: 10.1111/apha.12200. Epub 2013 Dec 12. — View Citation
Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Interventions for preventing critical illness polyneuropathy and critical illness myopathy. Cochrane Database Syst Rev. 2014 Jan 30;(1):CD006832. doi: 10.1002/14651858.CD006832.pub3. Review. — View Citation
Hirose T, Shiozaki T, Shimizu K, Mouri T, Noguchi K, Ohnishi M, Shimazu T. The effect of electrical muscle stimulation on the prevention of disuse muscle atrophy in patients with consciousness disturbance in the intensive care unit. J Crit Care. 2013 Aug;28(4):536.e1-7. doi: 10.1016/j.jcrc.2013.02.010. Epub 2013 Apr 3. — View Citation
Latronico N, Bertolini G, Guarneri B, Botteri M, Peli E, Andreoletti S, Bera P, Luciani D, Nardella A, Vittorielli E, Simini B, Candiani A. Simplified electrophysiological evaluation of peripheral nerves in critically ill patients: the Italian multi-centre CRIMYNE study. Crit Care. 2007;11(1):R11. — View Citation
Latronico N, Nattino G, Guarneri B, Fagoni N, Amantini A, Bertolini G; GiVITI Study Investigators. Validation of the peroneal nerve test to diagnose critical illness polyneuropathy and myopathy in the intensive care unit: the multicentre Italian CRIMYNE-2 diagnostic accuracy study. Version 3. F1000Res. 2014 Jun 11 [revised 2014 Jan 1];3:127. doi: 10.12688/f1000research.3933.3. eCollection 2014. — View Citation
Levine S, Nguyen T, Taylor N, Friscia ME, Budak MT, Rothenberg P, Zhu J, Sachdeva R, Sonnad S, Kaiser LR, Rubinstein NA, Powers SK, Shrager JB. Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. N Engl J Med. 2008 Mar 27;358(13):1327-35. doi: 10.1056/NEJMoa070447. — View Citation
Maddocks M, Gao W, Higginson IJ, Wilcock A. Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD009419. doi: 10.1002/14651858.CD009419.pub2. Review. Update in: Cochrane Database Syst Rev. 2016 Oct 17;10 :CD009419. — View Citation
Parry SM, Denehy L, Beach LJ, Berney S, Williamson HC, Granger CL. Functional outcomes in ICU – what should we be using? – an observational study. Crit Care. 2015 Mar 29;19:127. doi: 10.1186/s13054-015-0829-5. — View Citation
Routsi C, Gerovasili V, Vasileiadis I, Karatzanos E, Pitsolis T, Tripodaki E, Markaki V, Zervakis D, Nanas S. Electrical muscle stimulation prevents critical illness polyneuromyopathy: a randomized parallel intervention trial. Crit Care. 2010;14(2):R74. doi: 10.1186/cc8987. Epub 2010 Apr 28. — View Citation
Segers J, Hermans G, Bruyninckx F, Meyfroidt G, Langer D, Gosselink R. Feasibility of neuromuscular electrical stimulation in critically ill patients. J Crit Care. 2014 Dec;29(6):1082-8. doi: 10.1016/j.jcrc.2014.06.024. Epub 2014 Jun 30. — View Citation
Seymour JM, Ward K, Sidhu PS, Puthucheary Z, Steier J, Jolley CJ, Rafferty G, Polkey MI, Moxham J. Ultrasound measurement of rectus femoris cross-sectional area and the relationship with quadriceps strength in COPD. Thorax. 2009 May;64(5):418-23. doi: 10.1136/thx.2008.103986. Epub 2009 Jan 21. — View Citation
Skinner EH, Berney S, Warrillow S, Denehy L. Development of a physical function outcome measure (PFIT) and a pilot exercise training protocol for use in intensive care. Crit Care Resusc. 2009 Jun;11(2):110-5. — View Citation
* Note: There are 16 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Duration of respiratory support | The duration of ventilatory support is defined as the time in days, during which the patient requires invasive media type (continuous or not, intubation or tracheotomy and need the help of the respirator) or noninvasive (discontinuous or CPAP NIV (continuous positive airway pressure, noninvasive ventilation)- dependence). This will be assessed during the entire length of stay of the patient inside the intensive care unit (ICU). | Patients will be followed for the duration of their intensive care unit stay.The average duration of an intensive care unit stay in the CHU Brugamnn Hospital in 2014, all pathologies mixed, is 6 days. | |
Primary | Length of stay in the intensive care unit | Measured in days | Patients will be followed for the duration of their intensive care unit stay.The average duration of an intensive care unit stay in the CHU Brugamnn Hospital in 2014, all pathologies mixed, is 6 days. | |
Primary | Type of hospital discharge | Back to home or to a specialized long term care structure | At hospital discharge, within a maximum of two years (approximate study length). | |
Secondary | cross-sectional area of the rectus femoris | The quadriceps muscle mass will be assessed using an ultrasound system (PHILIPS, VIVIDS5). | First day in ICU | |
Secondary | cross-sectional area of the rectus femoris | The quadriceps muscle mass will be assessed using an ultrasound system (PHILIPS, VIVIDS5). | Third day in ICU | |
Secondary | cross-sectional area of the rectus femoris | The quadriceps muscle mass will be assessed using an ultrasound system (PHILIPS, VIVIDS5). | Fifth day in ICU | |
Secondary | cross-sectional area of the rectus femoris | The quadriceps muscle mass will be assessed using an ultrasound system (PHILIPS, VIVIDS5). | Seventh day in ICU | |
Secondary | cross-sectional area of the rectus femoris | The quadriceps muscle mass will be assessed using an ultrasound system (PHILIPS, VIVIDS5). | The day the patient is discharged from the intensive care unit. The average duration of an intensive care unit stay in the CHU Brugamnn Hospital in 2014, all pathologies mixed, is 6 days. | |
Secondary | Force index - Grip test | The "Grip Test" involves measuring the grip force developed by the hand of the patient, using a dynamometer (Neugen Medicals MODEL EH 101). This test will be conducted as soon as possible aka when the patient has -1 = RASS = 1, is sufficiently collaborating and little sedated. | Patients will be followed for the duration of their intensive care unit stay.The average duration of an intensive care unit stay in the CHU Brugamnn Hospital in 2014, all pathologies mixed, is 6 days. | |
Secondary | Force index - Grip test | The "Grip Test" involves measuring the grip force developed by the hand of the patient, using a dynamometer (Neugen Medicals MODEL EH 101). This test will be performed on the day the patient is discharged from the intensive care unit. | The day the patient is discharged from the intensive care unit. The average duration of an intensive care unit stay in the CHU Brugamnn Hospital in 2014, all pathologies mixed, is 6 days. | |
Secondary | Force index - Bike | The bike (Neugen Medicals MODEL EH 101) is a true "bike room" which facilitates active and passive mobilization of bedridden patients and allows, among other things, to measure the force developed by the patients and the ratio between active and passive labor work.This test will be conducted as soon as possible aka when the patient has -1 = RASS = 1, is sufficiently collaborating and little sedated. | Patients will be followed for the duration of their intensive care unit stay.The average duration of an intensive care unit stay in the CHU Brugamnn Hospital in 2014, all pathologies mixed, is 6 days. | |
Secondary | Force index - Bike | The bike (Neugen Medicals MODEL EH 101) is a true "bike room" which facilitates active and passive mobilization of bedridden patients and allows, among other things, to measure the force developed by the patients and the ratio between active and passive labor work.This will be measured at patient discharge from ICU | The day the patient is discharged from the intensive care unit. The average duration of an intensive care unit stay in the CHU Brugamnn Hospital in 2014, all pathologies mixed, is 6 days. | |
Secondary | Electromyogram | The Electrical conduction of nerves fibula will be assessed to detect nerve damage. A positive test will involve a complete electrophysiological monitoring by a specialist. | First day of ICU admission | |
Secondary | Electromyogram | The Electrical conduction of nerves fibula will be assessed to detect nerve damage. A positive test will involve a complete electrophysiological monitoring by a specialist. | Third day of ICU admission | |
Secondary | Electromyogram | The Electrical conduction of nerves fibula will be assessed to detect nerve damage. A positive test will involve a complete electrophysiological monitoring by a specialist. | Fifth day of ICU admission | |
Secondary | Electromyogram | The Electrical conduction of nerves fibula will be assessed to detect nerve damage. A positive test will involve a complete electrophysiological monitoring by a specialist. | Seventh day of ICU admission | |
Secondary | Electromyogram | The Electrical conduction of nerves fibula will be assessed to detect nerve damage. A positive test will involve a complete electrophysiological monitoring by a specialist. | The day the patient is discharged from the intensive care unit. The average duration of an intensive care unit stay in the CHU Brugamnn Hospital in 2014, all pathologies mixed, is 6 days. | |
Secondary | Physical Function ICU Test score (PFIT-s) | This simple functional test was developed to measure the functional abilities of patients severely debilitated that are found in the ICU. It consists in assessing four different levels of physical ability: the bending force of the shoulder and knee extension in sitting position, measured with the Oxford scale; the level of assistance needed to move from a sitting position to a standing position; and the ability to stand and walk on site. Patients will be tested as soon as possible aka when the patient has: -1 = RASS = 1, is sufficiently collaborating and not heavily sedated. | Patients will be followed for the duration of their intensive care unit stay.The average duration of an intensive care unit stay in the CHU Brugamnn Hospital in 2014, all pathologies mixed, is 6 days. | |
Secondary | Physical Function ICU Test score (PFIT-s) | This simple functional test was developed to measure the functional abilities of patients severely debilitated that are found in the ICU. It consists in assessing four different levels of physical ability: the bending force of the shoulder and knee extension in sitting position, measured with the Oxford scale; the level of assistance needed to move from a sitting position to a standing position; and the ability to stand and walk on site. | the day the patient is discharged from the intensive care unit. The average duration of an intensive care unit stay in the CHU Brugamnn Hospital in 2014, all pathologies mixed, is 6 days. | |
Secondary | Six minutes Walking Test | The 6-minute walk test is a validated and commonly used test to assess submaximal functional capacity; the test is conducted according to the guidelines of the American Thoracic Society. | the day the patient is discharged from the hospital, within a maximum of 2 years (approximate total study length) | |
Secondary | Six minutes Walking Test | The 6-minute walk test is a validated and commonly used test to assess submaximal functional capacity; the test is conducted according to the guidelines of the American Thoracic Society. | one year after the day of admission to the intensive care unit | |
Secondary | MOS SF-36 | The MOS SF-36 questionnaire will be proposed to patients on the day of hospital discharge and one year after the day of admission to the ICU, to assess their quality of life. | the day the patient is discharged from the hospital, within a maximum of two years (approximated study lenght) | |
Secondary | MOS SF-36 | The MOS SF-36 questionnaire will be proposed to patients on the day of hospital discharge and one year after the day of admission to the ICU, to assess their quality of life. | one year after the day of admission to the intensive care unit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05560555 -
Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045.
|
||
Recruiting |
NCT02033057 -
Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences.
|
Phase 4 | |
Completed |
NCT02442986 -
Neurological Outcome in Surgical and Non-surgical Septic Patients
|
N/A | |
Completed |
NCT02706314 -
Impact of Human Blood Serum From Critically Ill Patients on Human Colon Neuronal Networks.
|
||
Completed |
NCT01076478 -
Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines
|
Phase 4 | |
Completed |
NCT03373370 -
Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology
|
||
Completed |
NCT02846844 -
Patients With Chemotherapy-induced Polyneuropathy Are Treated With an Integrated Program Including Massage, Mobilization in Posture and Transport Layers, Physical Exercises or With Whole-body Vibration Platform Training
|
N/A | |
Recruiting |
NCT05950867 -
Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause.
|
N/A | |
Terminated |
NCT00832572 -
Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy
|
Phase 4 | |
Completed |
NCT00614562 -
Neurally Adjusted Ventilatory Assist (NAVA) in Patients With Critical Illness Associated Polyneuropathy / or Polymyopathy (CIP/M)
|
Phase 1 | |
Terminated |
NCT01088256 -
Efficacy of Etoricoxib on Peripheral Hyperalgesia
|
Phase 2 | |
Completed |
NCT01302275 -
Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain
|
Phase 4 | |
Not yet recruiting |
NCT01047488 -
Imipramine and Pregabalin Combination in Painful Polyneuropathy
|
Phase 4 | |
Recruiting |
NCT06414746 -
Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia
|
||
Completed |
NCT04201418 -
A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation
|
||
Completed |
NCT01450163 -
Evaluate The Efficacy and Safety Of Pregabalin In Prevention, Reduction of Oxaliplatin-Induced Painful Neuropathy
|
Phase 3 | |
Recruiting |
NCT05040373 -
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
|
||
Not yet recruiting |
NCT02666456 -
The Influence of Sensory Phenotype on the Risk of Developing Neuropathic Pain
|
N/A | |
Withdrawn |
NCT00723918 -
Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy
|
Phase 2 | |
Completed |
NCT00259974 -
RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy
|
Phase 3 |